S-1/A: Genprex Registers 1.28M Shares for Resale, Advances Gene Therapies

Genprex, a clinical-stage gene therapy company, filed an S-1/A to register 1.28 million shares for resale by selling stockholders, while detailing progress in its oncology and diabetes programs and recent financing activities.

Summary

• Registration of 1,280,088 shares of common stock for resale by selling stockholders, primarily from recent private placements and placement agent warrants.
• The company will not receive proceeds from the resale of these shares, but will receive proceeds from any cash exercise of the warrants.
• Genprex is a clinical-stage gene therapy company focusing on oncology (REQORSA for NSCLC and SCLC) and diabetes (GPX-002 for Type 1 and Type 2 diabetes).
• Acclaim-1 (NSCLC) Phase 2a expansion is ongoing, with interim analysis expected in the second half of 2026. The trial has FDA Fast Track Designation.
• Acclaim-2 (NSCLC) enrollment was ceased in August 2024 due to challenges and resource prioritization.
• Acclaim-3 (ES-SCLC) Phase 2 expansion is ongoing, with interim analysis expected in the second half of 2026. It has FDA Fast Track and Orphan Drug Designations.
• The diabetes program (GPX-002) is in preclinical studies, with plans to request an FDA meeting for IND-enabling studies by the end of 2025.
• The company completed a 1:50 reverse stock split effective October 21, 2025.
• Recent financing activities include an Equity Line of Credit (ELOC) with Lincoln Park Capital Fund, LLC, and two registered direct offerings in October 2025, raising approximately $5.6 million in net proceeds from the direct offerings (excluding warrant exercises).
• Genprex regained compliance with Nasdaq's $1.00 Minimum Bid Price requirement but has an exception until December 31, 2025, to comply with the Stockholders Equity Requirement, and anticipates needing additional capital for this.

Sentiment

Score: 4

Explanation: While there is positive clinical progress in Acclaim-1 and Acclaim-3, including FDA designations and promising patient responses, the cessation of Acclaim-2 due to enrollment issues and the ongoing 'going concern' warning from auditors, coupled with the need for further capital to meet Nasdaq listing requirements, indicate significant financial and operational headwinds. The capital raises are necessary but also dilute existing shareholders.

Positives

• REQORSA (Acclaim-1) showed prolonged progression-free survival in Phase 1, with one patient maintaining partial remission for approximately 39 months.
• Both Acclaim-1 and Acclaim-3 clinical trials have received FDA Fast Track Designation, potentially accelerating development and review.
• Acclaim-3 also received FDA Orphan Drug Designation, which can provide market exclusivity and other incentives.
• Successful completion of Phase 1 dose escalation for Acclaim-1 and Acclaim-3, determining the Recommended Phase 2 Dose (RP2D) at 0.12 mg/kg without dose-limiting toxicities.
• Positive preclinical data for GPX-002 in a non-human primate model of Type 1 diabetes, showing decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance.
• Regained compliance with Nasdaq's $1.00 Minimum Bid Price requirement.
• Secured recent financing through an Equity Line of Credit and two registered direct offerings in October 2025, providing capital for operations.

Negatives

• Ceased enrollment in the Acclaim-2 trial due to enrollment challenges, delays, and competition for patients, indicating potential difficulties in clinical trial execution.
• The company's auditor's report includes an explanatory paragraph regarding its ability to continue as a going concern, highlighting financial uncertainty.
• Still needs to demonstrate long-term compliance with Nasdaq's Stockholders Equity Requirement by December 31, 2025, and believes additional capital raising will be necessary.
• The company will not receive any proceeds from the resale of the 1,280,088 shares registered in this S-1/A, only from the cash exercise of warrants.
• The reverse stock split (1:50) indicates a need to boost share price to maintain Nasdaq listing, often viewed negatively by investors.
• The company has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future.

Risks

• Investing in common stock involves a high degree of risk.
• Uncertainty regarding the ability to raise additional future financing and possible lack of financial and other resources to support development programs and business growth.
• Ability to continue as a going concern.
• Ability to regain and maintain compliance with Nasdaq's continued listing requirements.
• Ability to compete effectively with larger and/or better-financed biotechnology and pharmaceutical companies.
• Uncertainty of developing marketable products and obtaining regulatory approvals.
• Ability and third-parties' ability to maintain and protect intellectual property rights.
• The effects and impacts of public health crises such as epidemics or outbreaks, which could significantly disrupt and have a materially adverse effect upon business, clinical trials, and research programs.
• The success of clinical trials through all phases of clinical development, including the ability of third-party suppliers or manufacturers to supply or manufacture products on a timely, consistent basis.
• Any delays in regulatory review and approval of current and future product candidates.
• Dependence on third-party suppliers or manufacturers to supply or manufacture key ingredients and/or raw materials, products and/or product components.
• Ability to control product development costs.
• Ability to attract and retain key employees.
• Ability to enter into new strategic collaborations, licensing or other arrangements.
• Changes in government regulation affecting product candidates that could increase development costs.
• Involvement in patent, trademark and other intellectual property litigation that could be expensive and divert management's attention.
• The possibility that there may be no market acceptance for products.
• Changes in third-party reimbursement policies which could adversely affect potential future sales of any approved products.
• Anti-takeover effects of charter documents and Delaware law could delay or prevent a change in control.

Future Outlook

Expect to complete enrollment for interim analysis in Acclaim-1 Phase 2a and Acclaim-3 Phase 2 in the first half of 2026, with interim analyses for both studies in the second half of 2026. Plan to submit a request to the FDA for a meeting regarding IND-enabling studies for the diabetes program by the end of 2025. The company intends to retain all available funds and future earnings for business operations and does not anticipate paying dividends in the foreseeable future. The company believes it will need to engage in additional capital raising transactions to regain compliance with the Nasdaq Stockholders Equity Requirement.

Management Comments

• "We continue to believe that this combination [REQORSA and Keytruda] could be beneficial." (Regarding Acclaim-2, despite ceasing enrollment).
• "The Company believes it will need to engage in additional capital raising transactions to regain compliance with the Stockholders Equity Requirement, and there is no guarantee that such financing will be available on terms acceptable to the Company, or at all."

Industry Context

Genprex operates in the highly competitive and rapidly changing gene therapy and oncology/diabetes treatment sectors. The company's strategy of combining its gene therapy (REQORSA) with prominent, approved cancer drugs (Tagrisso, Tecentriq) aligns with a trend in oncology to improve existing therapies through combination approaches. The focus on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) addresses significant unmet medical needs, particularly for patients who have progressed on standard treatments. The diabetes gene therapy program, aiming to transform alpha cells into functional beta-like cells or rejuvenate exhausted beta cells, represents an innovative approach in a field with high demand for new treatments. Enrollment challenges in Acclaim-2 highlight the competitive landscape for clinical trial participants, especially in common patient populations, which is a known industry hurdle.

Corporate Governance

Related Party Transactions

• Issuance of First Placement Agent Warrants to H.C. Wainwright & Co., LLC (or its designees) for 14,617 shares of common stock with an exercise price of $14.0125 per share in connection with the First Private Placement and concurrent registered direct financing transaction.
• Issuance of Second Placement Agent Warrants to H.C. Wainwright & Co., LLC (or its designees) for 22,667 shares of common stock with an exercise price of $11.25 per share in connection with the Second Private Placement and concurrent registered direct financing transaction.
• Agreement to pay H.C. Wainwright & Co., LLC a cash fee equal to 7.0% and a management fee equal to 1.0% of the aggregate gross exercise price paid in cash with respect to the exercise of Second Private Warrants.
• Agreement to issue H.C. Wainwright & Co., LLC (or its designees) additional placement agent warrants to purchase a number of shares equal to 6.0% of the aggregate number of shares of common stock underlying Second Private Warrants that have been exercised.
• Issuance of common stock and warrants to consultants and the Chairman of the Scientific Advisory Board in consideration for services.

Stakeholder Impact

• Shareholders face potential dilution from the exercise of warrants and future capital raises. The reverse stock split impacts share count and price per share. Nasdaq compliance issues create uncertainty regarding continued listing.
• Investors face a high degree of risk due to the early-stage nature of products, the 'going concern' warning, and the need for significant future financing.
• Employees and management are under pressure to advance clinical programs, secure financing, and achieve regulatory milestones.
• Patients may benefit from new gene therapies for NSCLC, SCLC, and diabetes if clinical trials are successful.
• University of Texas MD Anderson Cancer Center and University of Pittsburgh maintain collaboration and licensing agreements for core technologies.

Next Steps

• Complete enrollment of the first 19 patients for interim analysis in Acclaim-1 Phase 2a in the first half of 2026.
• Conduct interim analysis for Acclaim-1 Phase 2a in the second half of 2026.
• Complete enrollment of the first 25 patients for interim analysis in Acclaim-3 Phase 2 in the first half of 2026.
• Conduct interim analysis for Acclaim-3 Phase 2 in the second half of 2026.
• Submit a request to the FDA to meet regarding IND-enabling studies for the diabetes program by the end of 2025.
• Engage in additional capital raising transactions to regain compliance with the Nasdaq Stockholders Equity Requirement.
• Provide prompt notification to the Nasdaq Panel of any significant events that may call into question the company's ability to satisfy the terms of the Stockholders Equity Requirement exception.
• Potentially request a further extension beyond December 31, 2025, to regain compliance with the Stockholders Equity Requirement.

Key Dates

Recommendation

The company is in a high-risk, high-reward sector. While there are promising clinical developments (Acclaim-1 and Acclaim-3 progress, FDA designations, positive preclinical diabetes data), significant financial challenges persist, including a 'going concern' warning from auditors and the explicit need for further capital to maintain Nasdaq listing. The cessation of Acclaim-2 is a setback. The recent capital raises provide some runway but also involve dilution. For a seasoned investor, the current situation warrants a 'Hold' to observe how the company addresses its financial stability and progresses its key clinical programs, particularly the interim analyses expected in the second half of 2026. The long-term potential is there, but the near-term risks are substantial.

Keywords

gene therapy, oncology, diabetes, NSCLC, SCLC, REQORSA, GPX-002, clinical trials, biotechnology, Nasdaq compliance, reverse stock split, warrants, private placement, capital raise, FDA Fast Track, Orphan Drug Designation